CIP
BIO icon

Champlain Investment Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Champlain Investment Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-256,730
Closed -$97.3M – 127
2023
Q2 		$97.3M Buy
256,730
+39,065
+18% +$15.9M 0.6% 72
2023
Q1 		$104M Sell
217,665
-1,060
-0.5% -$496K 0.66% 64
2022
Q4 		$92M Sell
218,725
-4,965
-2% -$2M 0.59% 75
2022
Q3 		$93.3M Sell
223,690
-4,820
-2% -$2.4M 0.64% 69
2022
Q2 		$113M Sell
228,510
-15,995
-7% -$8.33M 0.73% 59
2022
Q1 		$138M Sell
244,505
-270
-0.1% -$163K 0.71% 62
2021
Q4 		$185M Sell
244,775
-6,000
-2% -$4.49M 0.84% 46
2021
Q3 		$187M Sell
250,775
-10,540
-4% -$7.9M 0.9% 40
2021
Q2 		$168M Buy
261,315
+1,915
+0.7% +$1.17M 0.8% 50
2021
Q1 		$148M Buy
259,400
+26,155
+11% +$15.5M 0.77% 54
2020
Q4 		$136M Buy
233,245
+25,375
+12% +$14.5M 0.78% 56
2020
Q3 		$107M Buy
207,870
+5,720
+3% +$2.9M 0.73% 60
2020
Q2 		$91.3M Buy
202,150
+99,425
+97% +$43.9M 0.66% 60
2020
Q1 		$36M Buy
+102,725
New +$37.8M 0.32% 98
2015
Q1 		– Sell
-108,830
Closed -$13.1M – 132
2014
Q4 		$13.1M Sell
108,830
-593,695
-85% -$68.3M 0.21% 115
2014
Q3 		$79.7M Sell
702,525
-123,630
-15% -$14.6M 1.38% 12
2014
Q2 		$98.9M Buy
826,155
+26,345
+3% +$3.22M 1.62% 10
2014
Q1 		$102M Buy
799,810
+17,415
+2% +$2.23M 1.76% 7
2013
Q4 		$96.7M Sell
782,395
-1,735
-0.2% -$211K 1.7% 8
2013
Q3 		$92.2M Buy
784,130
+42,835
+6% +$5.05M 1.75% 4
2013
Q2 		$83.2M Buy
+741,295
New +$87M 1.68% 5

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Champlain Investment Partners's BIO Position: Q3 2023 in Review

Champlain Investment Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2023, closing a stake of 256,730 shares — an estimated $97.3M sold.

Champlain Investment Partners first reported a position in BIO in Q2 2013 and held it in 21 quarters. The position peaked at $187M in Q3 2021. 468 funds tracked by Wall St. Rank hold BIO as of Q3 2023.

  • Champlain Investment Partners reported no remaining Bio-Rad Laboratories Class A position as of Q3 2023 after selling out during the quarter.
  • Champlain Investment Partners sold 256,730 Bio-Rad Laboratories Class A shares in Q3 2023, an estimated $97.3M.
  • Champlain Investment Partners first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 21 quarters.
  • Champlain Investment Partners's Bio-Rad Laboratories Class A position peaked at $187M in Q3 2021.
  • 468 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2023.

Based on Champlain Investment Partners's 13F filing for Q3 2023, filed 13 Nov 2023.